在初级PCI期间使用比瓦利鲁丁对抗凝血剂与肝素的BMI差异:a BRIGHT-4亚分析
Dali Zhang1, Yi Li1, Miaohan Qiu1
1State Key Laboratory of Frigid Zone Cardiovascular Diseases, Department of Cardiology, General Hospital of Northern Theater Command, Cardiovascular Research Institute, Shenyang, 110016, China.
BMC medicine
|October 1, 2025
概括
比瓦利鲁丁治疗减少了ST段升高心肌梗塞 (STEMI) 患者的死亡或严重出血,这些患者的体重指数 (BMI) 较低,正在接受皮肤冠状动脉干预 (PCI). 在BMI较高的患者中没有观察到这种益处.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 身体质量指数 (BMI) 影响ST段升高心肌梗塞 (STEMI) 患者的缺血和出血风险.
- BRIGHT-4试验表明,与氨酸单独治疗相比,用长时间高剂量输注的比瓦利鲁丁抗凝药可以减少死亡率和严重出血.
研究的目的:
- 评估比瓦利鲁丁与肝素在接受初级PCI的STEMI患者中的疗效,特别是根据基线身体质量指数 (BMI) 分层分析结果.
- 为了确定比瓦利鲁丁的好处,包括降低死亡率和出血,在不同BMI类别中是否一致.
主要方法:
- 对来自BRIGHT-4试验 (NCT03822975) 的6016名随机 STEMI 患者进行了亚组分析.
- 患者根据基线BMI (<25 kg/m2 vs. ≥25 kg/m2) 进行了分层.
- 比瓦利鲁丁的治疗效应 (高剂量输注2至4小时) 与肝素单一治疗进行了比较,主要使用放射性动脉接入.
主要成果:
- 主要终点 (全因死亡或学术研究联盟 (BARC) 类型的出血30天后3-5次出血) 在BMI≥25kg/m2的患者中较少发生,而BMI<25kg/m2 (未调整分析) 的患者则较少发生.
- 与肝素相比,在BMI<25 kg/m2 (调整HR0.56) 的患者中,比瓦利鲁丁显著降低了主要终点.
- 在BMI≥25kg/m2 (调整HR为0.97) 的患者中没有观察到比瓦利鲁丁的显著益处,统计学上显著的相互作用 (Pinteraction=0.04).
结论:
- 随着长期高剂量输注的比瓦利鲁丁抗凝剂,在接受初级PCI的STEMI患者中,降低BMI的STEMI患者的死亡或严重出血的复合终点显著降低.
- 在BMI较高的患者中,比瓦利鲁丁对肝素所观察到的益处并不显著,这表明这种抗凝血策略的潜在BMI依赖作用.
- 这些发现强调了在选择初级PCI的STEMI患者抗凝治疗时考虑患者的BMI的重要性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Venous Thrombosis IV: Nursing Management
201
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
201
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
328
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
328


